Anaphylaxis following quadrivalent human papillomavirus vaccination

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 6, 2008, Pages 525-533

  Brotherton, Julia M L ^a,d   Gold, Mike S ^b   Kemp, Andrew S ^a   McIntyre, Peter B ^a   Burgess, Margaret A ^a   Campbell Lloyd, Sue ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c New South Wales Government   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; POLYSORBATE 80; SALBUTAMOL; WART VIRUS VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGITATION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; AUSTRALIA; BLURRED VISION; CHEST TIGHTNESS; COLD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAPHORESIS; DIZZINESS; DRUG ERUPTION; DRY THROAT; DYSPHAGIA; DYSPNEA; FEMALE; FLUSHING; HEPATITIS B; HOARSENESS; HUMAN; HYPOXIA; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE RASH; INTERVIEW; LABOUR RESPIRATION; MEDICAL RECORD REVIEW; MENINGOCOCCOSIS; NAUSEA; PRICK TEST; PRURITUS; SCHOOL CHILD; SHIVERING; SIDE EFFECT; SKIN ALLERGY; SKIN TEST; STRIDOR; SYNCOPE; TACHYCARDIA; TACHYPNEA; TELEPHONE; THORAX PAIN; THROAT IRRITATION; URTICARIA; VACCINATION; VOMITING; WHEEZING;

EID: 51649102309     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080916     Document Type: Article

References (41)

1. Babl FE, Lewena S, Brown L. Vaccination-related adverse events. Pediatr Emerg Care 2006;22:514-9.
2. Rüggeberg JU, Gold MS, Bayas JM, et al. The Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5675-84.
3. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-7.
4. World Health Organization. Adverse events following immunization: causality assessment. Geneva: The Organization; 2008. Available: www.who.int/vaccinesdocuments/DocsPDF05/815.pdf (accessed 2008 July 21).
5. D'Souza RM, Campbell-Lloyd S, Isaacs D, et al. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. Commun Dis Intell 2000;24:27-33.
6. Dobson S, Scheifele D, Bell A. Assessment of a universal, school-based hepatitis B vaccination program. JAMA 1995;274:1209-13.
7. Salisbury DM, Campbell H, Edwards B. Measles rubella immunisation campaign in England "one year on." London (UK): Department of Health; 1995.
8. Sakaguchi M, Nakayama T, Fujita H, et al. Minimum estimated incidence in Japan of anaphylaxis to live virus vaccines including gelatin. Vaccine 2000;19:431-6.
9. Patja A, Davidkin I, Kurki T, et al. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J 2000;19:1127-34.
10. Patja A, Mäkinen-Kiljunen S, Davidkin I, et al. Allergic reactions to measles-mumps-rubella vaccination. Pediatrics 2001;107:e27.
11. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003;112:815-20.
12. Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007;25:570-6.
13. Pool V, Braun MM, Kelso JM, et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics 2002;110:e71.
14. Department of Health. Vaccine safety and the management of adverse events following immunisation. In: Salisbury D, Ramsay M, Noakes K, eds. Immunisation against infectious disease: "The Green Book." London (UK): The Stationery Office; 2006. p. 53-64. Available: www.dh.gov.uk/en/Publichealth/Healthprotection/Immunisation/Greenbook/ DH_4097254 (accessed 2008 May 23).
15. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Surveill Summ 2003;52:1-24.
16. Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999;103:698-701.
17. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP-an ultimate solution for vaccine-related gelatin allergy. Biologicals 2003;31:245-9.
18. Miller NB, US Food and Drug Authority. Clinical review of Biologics License Application for Human papillomavirus 6, 11, 16, 18 L1 virus like particle vaccine (S. cerevisiae) (STN 125126 GARDASIL), manufactured by Merck, Inc. 2006. Available: www.fda.gov/cber/review/hpvmer060806r.pdf (accessed 2008 July 21).
19. Huang WT, Leidel L, Vellozi C, et al. Safety review of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine [poster abstract 150]. International Conference on Emerging Infectious Diseases 2008; Mar. 16-19; Atlanta (GA). Available: www.cdc.gov/eid/content/14/3/ICEID2008.pdf (accessed 2008 July 21).
20. Poulos LM, Waters AM, Correll PK, et al. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. J Allergy Clin Immunol 2007;120:878-84.
21. Sheikh A, Alves B. Age, sex, geographical and socio-economic variations in admissions for anaphylaxis: analysis of four years of English hospital data. Clin Exp Allergy 2001;31:1571-6.
22. Siegrist CA, Lewis EM, Eskola J, et al. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007;26:979-84.
23. DiMiceli L, Pool V, Kelso JM, et al. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006;24:703-7.
24. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006;24(Suppl 3):S106-13.
25. Emeny RT, Wheeler CM, Jansen KU, et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 2002;76:7832-42.
26. Ruiz W, McClements WL, Jansen KU, et al. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminium adjuvant. J Immune Based Ther Vaccines 2005;3:1-11.
27. Rissel CE, Richters J, Grulich AE, et al. Sex in Australia: selected characteristics of regular sexual relationships. Aust N Z J Public Health 2003;27:124-30.
28. Airola K, Petman L, Makinen-Kiljunen S. Clustered sensitivity to fungi: anaphylactic reactions caused by ingestive allergy to yeasts. Ann Allergy Asthma Immunol 2006;97:294-7.
29. Systemic adverse effects of hepatitis B vaccines are rare. Prescrire Int 2004;13: 218-23.
30. Brightman CA, Scadding GK, Dumbreck LA, et al. Yeast-derived hepatitis B vaccine and yeast sensitivity. Lancet 1989;333:903.
31. Hudson TJ, Newkirk M, Gervais F, et al. Adverse reaction to the recombinant hepatitis B vaccine. J Allergy Clin Immunol 1991;88:821-2.
32. Barbaud A, Trechot P, Reichert-Penetrat S, et al. Allergic mechanisms and urticaria/ angioedema after hepatitis B immunization. Br J Dermatol 1998;139:925-6.
33. Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007;25:3001-6.
34. Grims RH, Kranke B, Aberer W. Pitfalls in drug allergy skin testing: false-positive reactions due to (hidden) additives. Contact Dermatitis 2006;54:290-4.
35. ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85.
36. Steele RH, Limaye S, Cleland B, et al. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology 2005;10:317-20.
37. Coors EA, Seybold H, Merk HF, et al. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 2005;95:593-9.
38. Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004;4:84-90.
39. Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med 1997;151:255-9.
40. Walker S, Sheikh A. Managing anaphylaxis: effective emergency and long-term care are necessary. Clin Exp Allergy 2003;33:1015-8.
41. Therapeutic Goods Administration. Human papillomavirus vaccine (Gardasil). Advice from the Therapeutic Goods Administration. Australia: The Administration; 2008. Available: www.tga.gov.au/alerts/medicines/gardasil.htm (accessed 2008 Aug 6).